BiotechTube
Home/Telomir Pharmaceuticals/Matthew Pratt Whalen
MP

Matthew Pratt Whalen

Director

Telomir Pharmaceuticals

Therapeutic Areas

Longevity / AgingMetabolic DiseaseRare Genetic DiseasesNeurodegenerationOphthalmology

Telomir Pharmaceuticals Pipeline

DrugIndicationPhase
Telomir-1Age-Related Degeneration / LongevityPre-clinical

Leadership Team at Telomir Pharmaceuticals

EA
Erez Aminov
Chairman and Chief Executive Officer
AW
Alan Weichselbaum
Chief Financial Officer
IA
Itzchak Angel
Chief Scientific Advisor
AW
Alex Weisman
Scientific Advisor
NM
Ned MacPherson
Director
MP
Matthew P. Del Giudice
Director
FE
Francis E. O’Donnell, Jr.
Senior Advisor
PM
Peter McDonnell
Special Advisor
MR
Michael Roizen
Special Advisor
View full Telomir Pharmaceuticals profile